Multi-institutional study to evaluate the usefulness of proton therapy for intracranial tumors using normal tissue complication probability model
Not Applicable
Completed
- Conditions
- Glioma, Meningioma
- Registration Number
- JPRN-UMIN000052664
- Lead Sponsor
- Hokkaido university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
Not provided
Exclusion Criteria
1. Persons of nationality other than Japan 2. Persons who underwent hyperfractionated irradiation (irradiation twice a day) 3. Persons who received proton beam therapy as private practice 4. Persons who have undergone proton beam therapy to areas with a history of radiation therapy 5. Other persons deemed unsuitable as research subjects by the research director
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie proton therapy's efficacy in glioma and meningioma treatment?
How does proton therapy compare to photon therapy in managing intracranial tumors like glioblastoma?
Which biomarkers are used to select patients for proton therapy in the MBAPT-CNS trial?
What are the potential adverse events associated with proton therapy for meningioma and glioma?
Are there combination approaches involving proton therapy and targeted agents for CNS tumors?